Beneficial ownership — 13D / 13G
87,339 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.
Coverage begins December 2024, when the SEC required these schedules to be filed as structured XML.
| Reporting person | Issuer | Schedule | % of class | Event date | Filed |
|---|---|---|---|---|---|
| BBAI Ultimate Holdings, LLC | BBAI BigBear.ai Holdings, Inc. | 13D/A | 64.8% | Mar 8, 2024 | 2y |
| Cormorant Asset Management, LP | CRBP Corbus Pharmaceuticals Holdings, Inc. | 13G/A | 19.3% | Mar 8, 2024 | 2y |
| GLAZER CAPITAL, LLC | HARP Harpoon Therapeutics, Inc. Common Stock | 13G | 0% | Mar 8, 2024 | 2y |
| SCOGGIN MANAGEMENT LP | WKSP Worksport Ltd | 13G | 2.46% | Mar 7, 2024 | 2y |
| John C. Klock, Jr. | QTI Qt Imaging Holdings, Inc. | 13D | 13.4% | Mar 4, 2024 | 2y |
| GigAcquisitions5, LLC | QTI Qt Imaging Holdings, Inc. | 13D | 33.7% | Mar 4, 2024 | 2y |
| Aquilo Capital Management, LLC | DTIL Precision Biosciences Inc | 13G | 9.9% | Mar 1, 2024 | 2y |
| A.L. Sarroff Fund, LLC | PETV PetVivo Holdings, Inc. | 13G/A | 11.75% | Feb 9, 2024 | 2y |
| M&G INVESTMENT MANAGEMENT LTD | CRGO Freightos Ltd | 13D | 19.5% | Feb 8, 2024 | 2y |
| Tal Barnoach | BMR Beamr Imaging Ltd. | 13G | 7.4% | Dec 31, 2023 | 2y |
| Scott Tarriff | EGRX Eagle Pharmaceuticals, Inc. | 13G/A | 17.6% | Dec 31, 2023 | 2y |
| Timothy J. Langer | TSBX Turnstone Biologics Corp. Common Stock | 13G | 5.6% | Sep 11, 2023 | 2y |
| GIP II Blue Holding, L.P. | HESM Hess Midstream LP | 13D/A | 43.3% | Mar 14, 2024 | 2y |
| Deerfield Management Company, L.P. | LRMR Larimar Therapeutics, Inc. | 13D/A | 33.32% | Mar 14, 2024 | 2y |
| INCLUSIVE CAPITAL PARTNERS, L.P. | STRA Strategic Education, Inc. | 13D/A | 6.7% | Mar 14, 2024 | 2y |
| Hess Investments North Dakota LLC | HESM Hess Midstream LP | 13D/A | 51.8% | Mar 14, 2024 | 2y |
| Stellantis N.V. | ACHR Archer Aviation Inc. | 13D/A | 16.5% | Mar 13, 2024 | 2y |
| Michael B. Chancellor | LIPO Lipella Pharmaceuticals Inc. | 13D/A | 20% | Mar 13, 2024 | 2y |
| CB SNOWBIRD HOLDINGS, L.P. | HCI HCI Group, Inc. | 13D/A | 4.76% | Mar 13, 2024 | 2y |
| Gerald E. O’Shaughnessy | GPRK GeoPark Ltd | 13D/A | 5.05% | Mar 13, 2024 | 2y |
| Jonathan H. Kaufman | LIPO Lipella Pharmaceuticals Inc. | 13D/A | 19.5% | Mar 13, 2024 | 2y |
| UDQ Private Trust Company, LLC, solely as trustee of the trusts listed on Appendix A -1 and Appendix A-2. | H Hyatt Hotels Corp | 13D/A | 17.3% | Mar 13, 2024 | 2y |
| Dragasac Ltd | CELU Celularity Inc | 13D/A | 34.2% | Mar 13, 2024 | 2y |
| Fund 1 Investments, LLC | BJRI BJs RESTAURANTS INC | 13D/A | 9.96% | Mar 13, 2024 | 2y |
| Mark Comora | OPAL OPAL Fuels Inc. | 13D/A | 84.2% | Mar 12, 2024 | 2y |
| Saba Capital Management, L.P. | HQH abrdn Healthcare Investors | 13D | 5.17% | Mar 12, 2024 | 2y |
| Joseph Reda | UAVS AgEagle Aerial Systems Inc. | 13G | 6.16% | Mar 11, 2024 | 2y |
| White Lion Capital, LLC | AUUD Auddia Inc. | 13G | 9.77% | Mar 11, 2024 | 2y |
| David B. Blundin | EVER EverQuote, Inc. | 13D/A | 25.9% | Mar 11, 2024 | 2y |
| Jean-Pierre De Villiers | LEAT Leatt Corp | 13D/A | 0.4% | Mar 8, 2024 | 2y |
| Deep Track Capital, LP | DFTX Definium Therapeutics, Inc. | 13G | 9.49% | Mar 7, 2024 | 2y |
| GENERAL ATLANTIC, L.P. | AKRO Akero Therapeutics, Inc. Common Stock | 13G | 7.7% | Mar 6, 2024 | 2y |
| TCG Crossover GP II, LLC | NKTR Nektar Therapeutics | 13G | 9.9% | Mar 6, 2024 | 2y |
| Tontine Capital Partners, L.P. | IESC IES Holdings, Inc. | 13D/A | 56.4% | Mar 6, 2024 | 2y |
| Cowen Overseas Investment LP 000000000 | STHO Star Holdings | 13G/A | 7.34% | Mar 6, 2024 | 2y |
| MFN Partners, LP | SBNY Signature Bank | 13G | 9.5% | Mar 6, 2024 | 2y |
| American Industrial Partners Capital Fund IV, LP | REVG REV Group, Inc. | 13G/A | 3.4% | Feb 20, 2024 | 2y |
| Michael Bigger | BFRI Biofrontera Inc. | 13G | 9.99% | Feb 19, 2024 | 2y |
| Cowen Overseas Investment LP 000000000 | STHO Star Holdings | 13G/A | 8.13% | Dec 29, 2023 | 2y |
| Cowen Overseas Investment LP 000000000 | STHO Star Holdings | 13G | 5.08% | Jul 5, 2023 | 2y |
| Lance S. Gad, Trustee, Lance S. Gad Revocable Trust U/A DTD 05/14/2018 | GYRO Gyrodyne, LLC | 13G | 7.6% | Mar 13, 2024 | 2y |
| TOWERVIEW LLC | GYRO Gyrodyne, LLC | 13G/A | 15.6% | Mar 13, 2024 | 2y |
| South Dakota Investment Council | VTOL Bristow Group Inc. | 13D/A | 16.4% | Mar 13, 2024 | 2y |
| Altria Group, Inc. | BUD Anheuser-Busch InBev SA | 13D/A | 57% | Mar 13, 2024 | 2y |
| Saba Capital Management, L.P. | NAC Nuveen California Quality Municipal Income Fund | 13D/A | 6.09% | Mar 12, 2024 | 2y |
| Columbia Capital IV, LLC | NN Nextnav Inc. | 13D/A | 7% | Mar 12, 2024 | 2y |
| Meridian Venture Partners II GP, L.P. ("GP") | ANIP Ani Pharmaceuticals Inc | 13D/A | 6.9% | Mar 12, 2024 | 2y |
| Oaktree Capital Holdings, LLC | TRMD TORM plc | 13D/A | 56.14% | Mar 12, 2024 | 2y |
| Onex Corporation | RYAN Ryan Specialty Holdings, Inc. | 13D/A | 3.5% | Mar 12, 2024 | 2y |
| LCP Edge Holdco, LLC | SKIN SkinHealth Systems Inc. | 13D/A | 27.03% | Mar 12, 2024 | 2y |